Prosensa, a late-stage biotech developing treatments for Duchenne muscular dystrophy, raised $78 million by offering 6.0 million shares at $13, the high end of the range of $11 to $13. Prosensa plans to list on the NASDAQ under the symbol RNA. Prosensa initially filed confidentially on 4/16/2013. J.P. Morgan and Citi were the joint bookrunners on the deal.
